Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients

BMC Genetics

Rong-cheng Luo¹  Lei Rong²  Hui-lin Wang³  Li-kuang Xiong³  Yu-li Chen⁴  Rong Li¹  Shao-ying Li¹ 

[1]TCM-Integrated Cancer Center of Southern Medical University, 510515 Guangzhou, People’s Republic of China

[2]Department of Breast Surgery, ShenZhen Maternal and Child Health Hospital, Shenzhen, People’s Republic of China

[3]Central Lab, Bao’an Maternal and Child Health Hospital, Shenzhen, People’s Republic of China

[4]Department of Women’s Health, Bao’an Maternal and Child Health Hospital, Shenzhen, People’s Republic of China

关键词: Biomarker;    Clinical outcome;    Breast cancer;    Methylation;    Protein tyrosine phosphatase receptor-type O (PTPRO);   

Others  :  866471
DOI  :  10.1186/1471-2156-15-67

 received in 2013-12-20, accepted in 2014-06-04,  发布年份 2014

【 摘 要 】

Background

Aberrant hypermethylation of gene promoter regions is a primary mechanism by which tumor suppressor genes become inactivated in breast cancer. Epigenetic inactivation of the protein tyrosine phosphatase receptor-type O gene (PTPRO) has been described in several types of cancer.

Results

We screened primary breast cancer tissues for PTPRO promoter hypermethylation and assessed potential associations with pathological features and patient outcome. We also evaluated its potential as a breast cancer biomarker. PTPRO methylation was observed in 53 of 98 (54%) breast cancer tissues but not in adjacent normal tissue. Among matched peripheral blood samples from breast cancer patients, 33 of 98 (34%) exhibited methylated PTPRO in plasma. In contrast, no methylated PTPRO was observed in normal peripheral blood from 30 healthy individuals. PTPRO methylation was positively associated with lymph node involvement (P = 0.014), poorly differentiated histology (P = 0.037), depth of invasion (P = 0.004), and HER2 amplification (P = 0.001). Multivariate analysis indicated that aberrant PTPRO methylation could serve as an independent predictor for overall survival hazard ratio (HR): 2.7; 95% CI: 1.1-6.2; P = 0.023), especially for patients with HER2-positive (hazard ratio (HR): 7.5; 95% CI: 1.8-31.3; P = 0.006), but not in ER + and PR + subpopulation. In addition, demethylation induced by 5-azacytidine led to gene reactivation in PTPRO-methylated and -silenced breast cancer cell lines.

Conclusions

Here, we report that tumor PTPRO methylation is a strong prognostic factor in breast cancer. Methylation of PTPRO silences its expression and plays an important role in breast carcinogenesis. The data we present here may provide insight into the development of novel therapies for breast cancer treatment. Additionally, detection of PTPRO methylation in peripheral blood of breast cancer patients may provide a noninvasive means to diagnose and monitor the disease.

【 授权许可】

   
2014 Li et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
• [2]Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A: Vaccine immunotherapy in breast cancer treatment:Promising, but still early. Expert Rev Anticancer Ther 2007, 7:1225-1241.
• [3]Emens LA, Reilly RT, Jaffee EM: Augmenting the potency of breast cancer vaccines: Combined modality immunotherapy. Breast Dis 2004, 20:13-24.
• [4]Dworkin AM, Huang TH, Toland AE: Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 2009, 19:165-171.
• [5]Hesson LB, Cooper WN, Latif F: The role of RASSF1A methylation in cancer. Dis Markers 2007, 23:73-87.
• [6]Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ, Holman K, James SJ, Jacob ST, Plass C: Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 2003, 22:6319-6331.
• [7]Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, Byrd JC, Grever M, Jacob ST: Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res 2007, 13:3174-3181.
• [8]Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, Suster S, Morrison C, Jacob ST: Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A 2004, 101:13844-13849.
• [9]Hogan LE, Meyer JA, Yang J, Wang J, Wong N, Yang W, Condos G, Hunger SP, Raetz E, Saffery R, Relling MV, Bhojwani D, Morrison DJ, Carroll WL: Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 2011, 118:5218-5226.
• [10]Ramaswamy B, Majumder S, Roy S, Wang J, Wong N, Yang W, Condos G, Hunger SP, Raetz E, Saffery R, Relling MV, Bhojwani D, Morrison DJ, Carroll WL: Estrogen-mediated suppression of the gene encoding protein tyrosine phosphatase PTPRO in human breast cancer: mechanism and role in tamoxifen sensitivity. Mol Endocrinol 2009, 23:176-187.
• [11]Yu M, Lin G, Arshadi N, Kalatskaya I, Xue B, Haider S, Nguyen F, Boutros PC, Elson A, Muthuswamy LB, Tonks NK, Muthuswamy SK: Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation. Mol Cell Biol 2012, 32:3913-3924.
• [12]Hunter T: Signaling–2000 and beyond. Cell 2000, 100:113-127.
• [13]Fischer EH: Cell signaling by protein tyrosine phosphorylation. Adv Enzyme Regul 1999, 39:359-369.
• [14]Laczmanska I, Sasiadek MM: Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim Pol 2011, V58N4:467-470.
• [15]Gupta S, Radha V, Sudhakar C, Swarup G: A nuclear protein tyrosine phosphatase activates p53 and induces caspase-1-dependent apoptosis. FEBS Lett 2002, 532:61-66.
• [16]Salmeen A, Andersen JN, Myers MP, Tonks NK, Barford D: Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B. Mol Cell 2000, 6:1401-1412.
• [17]Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T: Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711.
• [18]Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, Møller NP: Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 2001, 21:7117-7136.
• [19]Jacob ST, Motiwala T: Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy. Cancer Gene Ther 2005, 12:665-672.
• [20]You YJ, Chen YP, Zheng XX, Meltzer SJ, Zhang H: Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients. Cancer Lett 2012, 315:138-144.
• [21]Huang YT LIFF, Ke C, Li Z, Li ZT, Zou XF, Zheng XX, Chen YP, Zhang H: PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med 2013, 11:245. BioMed Central Full Text
• [22]Sobin LH, Wittekind C: International Union Against Cancer (UICC), 5th ed., TNM classification of malignant tumors. Baltimore (MD): Wiley-Liss; 1997:54-58.
• [23]Abd El-Rehim DM, Bal G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNAexpression analyses. Int J Cancer 2005, 116:340-350.
• [24]Li SY, Rong MN, Iacopetta B: DNA hypermethylation in breast cancer and its association with clinicopathological features. Cancer Lett 2006, 237:272-280.
• [25]Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996, 93:9821-9826.
• [26]Paulin R, Grigg G, Davey MW, Piper AA: Urea improves efficiency of bisulphate-mediated sequencing of 50-methylcytosine in genomic DNA. Nucleic Acids Res 1998, 26:5009-5010.
• [27]Motiwala T, Jacob ST: Role of protein tyrosine phosphatases in cancer. Prog Nucleic Acid Res Mol Biol 2006, 81:297-329.
• [28]Tonks NK: Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006, 7:833-846.
• [29]Ostman A, Hellberg Cand Bohmer FD: Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006, 6:307-320.
• [30]Hsu SH, Motiwala T, Roy S, Claus R, Mustafa M, Plass C, Freitas MA, Ghoshal K, Jacob ST: Methylation of the PTPRO gene in human hepatocellular carcinoma and identification of VCP as its substrate. J Cell Biochem 2013, 114:1810-1818.
• [31]Motiwala T, Majumder S, Ghoshal K, Kutay H, Datta J, Roy S, Lucas DM, Jacob ST: PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells. J Biol Chem 2009, 284:455-464.
• [32]Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y, Meltzer SJ: Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 2008, 123:2331-2336.
• [33]Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T, Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R, Abraham JM, Meltzer SJ: Hypermethylation of the AKAP12 promoter is a biomarker of Barrett’sassociated esophageal neoplastic progression. Cancer Epidemiol Biomarkers Prev 2008, 17:111-117.
• [34]Jin Z, Olaru A, Yang J, Sato F, Cheng Y, Kan T, Mori Y, Mantzur C, Paun B, Hamilton JP, Ito T, Wang S, David S, Agarwal R, Beer DG, Abraham JM, Meltzer SJ: Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 2007, 13:6293-6300.
• [35]Liu S, Sugimoto Y, Sorio C, Tecchio C, Lin YC: Function analysis of estrogenically regulated protein tyrosine phosphatase (PTPs) in human breast cancer cell line MCF-7. Oncogene 2004, 23:1256-1262.
• [36]Zheng J, Kulp SK, Zhang Y, Sugimoto Y, Dayton MA, Govindan MV, Brueggemeier RW, Lin YC: 17-Estradiol-regulated expression of protein tyrosine phosphatase gene in cultured human normal breast and breast cancer cells. Anticancer Res 2000, 20:11-19.
• [37]Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 2000, 21:427-433.
• [38]Dotzlaw H, Leygue E, Watson PH, Murphy LC: Estrogen receptor messenger RNA expression in human breast tumor biopsies: relationship to steroid receptor status and regulation by progestins. Cancer Res 1999, 59:529-532.
• [39]Iwao K, Miyoshi Y, Egawa C, Ikeda N, Noguchi S: Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 2000, 88:733-736.
• [40]Roger P, Sahla ME, Makela S, Gustafsson JA, Baldet P, Rochefort H: Decreased expression of estrogen receptor-β protein in proliferative preinvasive mammary tumors. Cancer Res 2001, 61:2537-2541.